Skip to content

SUPERNUS PHARMACEUTICALS, INC.

SUPN

CIK 0001356576 · Pharmaceutical Preparations · Nasdaq

  • SUPERNUS PHARMACEUTICALS INC (until 2019-06-12)
← back to feed
Revenue (TTM)
$715.09M
+8.6% YoY Q1 Apr 2026
Net Income (TTM)
−$36.74M
−152.2% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$0.65
−151.5% YoY Q1 Apr 2026
Gross Margin
89.5%
Q1 Apr 2026
Operating Margin
-9.3%
Q1 Apr 2026
Net Margin
-5.1%
Q1 Apr 2026
Free Cash Flow (TTM)
$183.8M
Q1 Apr 2026
Cash
$184.87M
Q1 Apr 2026
Total Debt
$401.44M
Q1 Apr 2026
Shares Outstanding
58.04M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings